natgillin/translations-raw huggingface dataset:
Patients with at least a partial response to adalimumab 40 mg weekly after 12 weeks of treatment. 
Bolniki z vsaj delnim odzivom na odmerek 40 mg adalimumaba po 12. tednih zdravljenja.
• worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness). 
• poslabšanje stanja, ki se imenuje dermatomiozitis (viden kot kožni izpuščaj, ki ga spremlja
This medicinal product contains less than 1 mmol of sodium (23 mg) per 0.8 mL dose, i.e. essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na 0,8 ml odmerek, kar v bistvu pomeni ‘brez
In all situations described below, the benefit/risk balance of therapy should be very carefully considered. 
V vseh spodaj opisanih okoliščinah je treba korist in tveganje zdravljenja z zdravilom Cyltezo zelo
Of those patients who had a response at week 8, 47 % were in response, 29 % were in remission, 41 % had mucosal healing, and 20 % were in steroid-free remission for ≥ 90 days at week 52. 
Od bolnikov, ki so bili odzivni v 8. tednu, jih je bilo v 52. tednu 47 % odzivnih, 29 % v remisiji, 41 % je imelo celjenje sluznice in 20 % jih je bilo v remisiji brez steroidov za ≥ 90 dni.
Improvement in quality of life was measured up to week 156 (36 months) and improvement was maintained through that time. 
Do 156. tedna (36. meseca) se je ocenjevalo izboljšanje kvalitete življenja, ki se je v tem
Efficacy Results at 12 Weeks, HS Studies I and II HS Study I 
Preglednica 21: Rezultati učinkovitosti v 12. tednu, HS študiji I in II
Patients remained on stable doses of NSAIDs and or prednisone (≤ 0.2 mg/kg/day or 10 mg/day maximum). 
Bolniki so ostali na stabilnih odmerkih nesteroidnih protivnetnih zdravil in/ali prednizona (≤ 0,2 mg/kg/dan ali največ 10 mg/dan).
• If needed, press cotton ball or gauze over injection site to stop any bleeding. 
• Po potrebi na mesto injiciranja pritisnite tampon ali gazo, da zaustavite morebitno krvavitev.
Among patients who were at least partial responders at week 12, and who received continuous weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3 % and at week 96 was 65.1 %. 
Med bolniki, ki z vsaj delnim odzivom v 12. tednu, in ki so prejemali neprekinjeno tedensko terapijo adalimumaba vsak teden, je bila stopnja kliničnega odziva (HiSCR) v 48. tednu 68,3 % in v 96. tednu 65,1 %.
In patients who develop HBV reactivation, Cyltezo should be stopped and effective anti-viral therapy with appropriate supportive treatment should be 
Pri bolnikih, ki se jim pojavi reaktivacija HBV, je treba uporabo zdravila Cyltezo prekiniti in uvesti učinkovito protivirusno terapijo z ustreznim podpornim
Patients who develop a new infection while undergoing treatment with Cyltezo should be monitored closely and undergo a complete diagnostic evaluation. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Cyltezo pojavi nova okužba, je treba natančno nadzirati in opraviti morajo popolno diagnostično obravnavo.
In rheumatoid arthritis, methotrexate is continued while using Cyltezo. 
Pri revmatoidnem artritisu se uporaba metotreksata med uporabo zdravila Cyltezo nadaljuje.
Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study UV I) or Week 2 (Study UV II) 
Kaplan-Meierjeve krivulje povzemajo čas do neuspeha zdravljenja v ali po 6. tednu (študija UV I) ali 2. tednu (študija UV II)
Antibiotics may be continued during treatment with Cyltezo if necessary. 
Med zdravljenjem z zdravilom Cyltezo lahko nadaljujete z antibiotičnim zdravljenjem, če je potrebno.
You should record the date when the syringe is first removed from refrigerator and the date after which it 
Zapisati si morate datum, ko je bila injekcijska brizga vzeta iz hladilnika in datum, po katerem jo je
The combination of Cyltezo and abatacept is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”). 
Kombinacija zdravila Cyltezo in abatacepta ni priporočljiva (glejte poglavje 4.4 "Sočasna uporaba bioloških DMARDS ali antagonistov TNF").
Cyltezo is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age. 
Zdravilo Cyltezo se uporablja za zdravljenje hidradenitis suppurativa pri odraslih in mladostnikih, starejših od 12 let.
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (see Table 29). 
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 29).
• If you have or develop a demyelinating disease (a disease that affects the insulating layer around the nerves, such as multiple sclerosis), your doctor will decide if you should receive or continue to receive Cyltezo. 
• Če imate ali pa se pri vas razvija demielinizirajoča bolezen (bolezen, ki vpliva na izolativno plast okoli živcev, kot je multipla skleroza), bo zdravnik presodil, ali lahko dobivate oziroma tudi še nadalje dobivate zdravilo Cyltezo.
• Use alcohol wipe to clean selected injection site. 
• Z alkoholnim zložencem očistite izbrano mesto injiciranja.
Hepato-biliary events 
Dogodki povezani s hepatobiliarnim sistemom
What Cyltezo looks like and contents of the pack 
Izgled zdravila Cyltezo in vsebina pakiranja
• Relevant information on the safety concerns of serious infections, sepsis, tuberculosis and opportunistic infections; congestive heart failure; demyelinating disorders; malignancies to be addressed by the additional risk minimisation measures (e.g. seriousness, severity, frequency, time to onset, reversibility of the AE as applicable). 
• Pomembne informacije glede varnostnih vprašanj v povezavi z resnimi okužbami, sepso, tuberkulozo in oportunističnimi okužbami, kongestivnim srčnim popuščanjem, demielinizirajočimi boleznimi, malignostmi, ki jih je treba nasloviti z ukrepi za dodatno zmanjševanje tveganj (npr. resnost, intenzivnost, pogostnost, čas do začetka, reverzibilnost
Treatment failure was defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual acuity (BCVA). 
Neuspeh zdravljenja je bil definiran z večkomponentnim izidom, ki je temeljil na vnetnih horioretinalnih in/ali vnetnih retinalnih vaskularnih lezijah, oceni celic sprednje očesne komore, motnosti steklovine in najboljši korigirani ostrini vida (BCVA, best corrected visual acuity).
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of pivotal studies was 5.9 % for patients taking adalimumab and 5.4 % for control treated 
Delež bolnikov, ki so zaradi neželenih učinkov prekinili zdravljenje med dvojno slepim, kontroliranim delom ključnih študij, ki podpirajo vlogo za pridobitev dovoljenja za promet, je bil 5,9 % v skupini, ki je prejemala adalimumab, in 5,4 % v kontrolni skupini.
• inflammation of the pancreas which causes severe pain in the abdomen and back; 
• vnetje trebušne slinavke, ki povzroča hujšo bolečino v trebuhu in hrbtu;
Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged), autoantibody test positive (including double stranded DNA antibody), blood lactate dehydrogenase increased 
pogosti motnje koagulacije in krvavenja (vključno s podaljšanim aktiviranim parcialnim tromboplastinskim časom), prisotnost avtoprotiteles (vključno s protitelesi proti dvovijačni DNA), zvišanje laktat dehidrogenaze v krvi
A single Cyltezo pre-filled syringe/pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. 
Posamezna napolnjena injekcijska brizga/napolnjeni injekcijski peresnik z zdravilom Cyltezo se lahko shranjuje pri temperaturi največ do 25 ºC za obdobje do 14 dni.
• angioedema (localised swelling of the skin); • lichenoid skin reaction (itchy reddish-purple skin rash). 
• angioedem (lokalizirano otekanje kože); • lihenoidna reakcija kože (srbeč rdeče-vijolični kožni izpuščaj).
Hepatosplenic T-cell lymphoma Merkel cell carcinoma (neuroendocrine carcinoma of the skin) 
levkemija hepatosplenični T-celični limfom karcinom Merklovih celic (nevroendokrini karcinom kože)
Distribution of patients by age and adalimumab dose received during the OL LI phase 
Porazdelitev bolnikov po starosti in odmerku adalimumaba, ki so ga dobivali med odprto uvajalno fazo Starostna skupina
Approximately twice the proportion of patients in the placebo group in the first 12 weeks of Studies HS-I and HS-II, compared with those in the adalimumab group experienced worsening of abscesses (23.0 % vs 11.4 %, respectively) and draining fistulas (30.0 % vs 13.9 %, respectively). 
Približno dvakratni delež bolnikov v skupini, ki je prejemala placebo, je v primerjavi s tistimi, ki so bili v skupini z adalimumabom, je v prvih 12. tednih študije HS-I in HS-II, doživelo poslabšanje abscesov (23,0 % v primerjavi z 11,4 %, v tem zaporedju) in fistul z izcedkom (30,0 % v primerjavi s 13,9 %, v tem zaporedju).
Patients should be tested for HBV infection before initiating treatment with Cyltezo. 
Bolnike je treba pred začetkom zdravljenja z zdravilom Cyltezo testirati na okužbo s HBV.
Of those in clinical response at week 4, 48 % had been previously exposed to other TNFantagonists. 
Od tistih, ki so imeli 4. teden klinični odziv, jih je 48 % predhodno dobilo antagoniste TNF.
Treatment with Cyltezo may result in the formation of autoimmune antibodies. 
Zdravljenje z zdravilom Cyltezo lahko povzroči nastanek avtoimunskih protiteles.
When combining controlled portions of these trials and ongoing and completed open label extension studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin cancers is approximately 8.5 per 1,000 patient-years. 
Če vzamemo skupaj kontrolirane dele teh preskušanj in potekajoče in zaključene nadaljevalne študije z mediano trajanja približno 3,3 leta s 6.427 bolniki in prek 26.439 bolnikov-let zdravljenja, je ugotovljeni delež malignomov (razen limfoma in nemelanomskih kožnih rakov) približno 8,5 na 1.000 bolnikov-let.
Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with Cyltezo. 
Bolnike je zato treba pred, med in po zdravljenju z zdravilom Cyltezo natančno kontrolirati glede okužb, vključno s tuberkulozo.
Melanoma and Merkel cell carcinoma have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8). 
Poročali so tudi o melanomu in karcinomu Merklovih celic pri bolnikih, zdravljenih z TNF-antagonisti, vključno z adalimumabom (glejte
Following 3 years of adalimumab therapy, 75 % (301/402) continued to be in clinical remission per partial Mayo score. 
Po 3 letih zdravljenja z adalimumabom jih je 75 % (301/402) ostalo v klinični remisiji po
Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician's Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 19). 
Ocena psoriaze nohtov je vključevala prilagojeni indeks izrazitosti psoriaze nohtov (mNAPSI, Modified Nail Psoriasis Severity Index), zdravnikovo globalno oceno psoriaze nohtov (PGA-F, Physician's Global Assessment of Fingernail Psoriasis) in indeks izrazitosti psoriaze nohtov (NAPSI, Nail Psoriasis Severity Index) (glejte preglednico 19).
Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least five months after the last Cyltezo treatment. 
Ženske v rodni dobi morajo premisliti o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še pet mesecev po zadnjem zdravljenju z zdravilom Cyltezo.
Although not statistically significant, the majority of patients demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender joint count (TJC), swollen joint count (SJC), Pediatric ACR 50 response, and Pediatric ACR 70 response. 
Čeprav ni statistično značilno, je bilo pri večini bolnikov dokazano klinično izboljšanje sekundarnih opazovanih dogodkov, kot so število mest entezitisa, število občutljivih sklepov, število oteklih sklepov, odziv glede na merila Pediatric ARC 50 in
The pivotal controlled studies involved 6,089 patients receiving adalimumab and 3,801 patients receiving placebo or active comparator during the controlled period. 
Ključne kontrolirane študije, ki podpirajo vlogo za pridobitev dovoljenja za promet, so vključevale 6.089 bolnikov, ki so med kontroliranim obdobjem dobivali adalimumab, in 3.801 bolnikov, ki so med tem obdobjem dobivali placebo ali primerjalno učinkovino.
• sensation of heart beating irregularly such as skipped beats; • heart problems that can cause shortness of breath or ankle swelling; 
• občutek neenakomernega bitja srca kot je preskakovanje utripov; • težave s srcem, ki lahko povzročijo kratko sapo ali otekanje gležnjev;
Once removed from the refrigerator for room temperature storage, the syringe must be used within 14 days or discarded, even if it is returned to the refrigerator. 
Ko jo enkrat, namesto v hladilniku, shranjujete pri sobni temperaturi, morate injekcijsko brizgo porabiti v 14 dneh ali pa jo zavreči, tudi če jo vrnete v hladilnik.
Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50 % reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline). 
Zmanjšanje vnetnih lezij in preprečevanje poslabšanja abscesov in fistul z izcedkom so ocenili z rezultatom kliničnega odziva pri hidradenitis suppurativa (HiSCR, Hidradenitis Suppurativa Clinical Response); najmanj 50 % zmanjšanje skupnega števila abscesov in vnetnih nodulov brez povečanja števila abscesov in fistul z izcedkom glede na izhodiščno število.
Cyltezo may have a minor influence on your ability to drive, cycle or use machines. 
Zdravilo Cyltezo ima lahko blag vpliv na sposobnost vožnje, kolesarjenja ali upravljanja strojev.
Excipients: sodium acetate trihydrate, glacial acetic acid, trehalose dihydrate, polysorbate 80 and water for injections. 
Pomožne snovi: natrijev acetat trihidrat, ledocetna kislina, trehaloza dihidrat, polisorbat 80 in voda za injekcije.
If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted. 
Če sumite na latentno tuberkulozo, se posvetujte z zdravnikom, ki ima izkušnje z zdravljenjem
After proper training in injection technique, patients may self-inject with Cyltezo if their physician determines that it is appropriate and with medical follow-up as necessary. 
Bolniki, ki se naučijo pravilnega postopka injiciranja, si zdravilo Cyltezo lahko injicirajo sami, če zdravnik presodi, da je to primerno, in je zagotovljeno ustrezno medicinsko spremljanje.
Longer term treatment with adalimumab 40 mg weekly for 96 weeks identified no new safety findings. 
Daljše, 96-tedensko zdravljenje z adalimumabom 40 mg na teden ni razkrilo novih izsledkov
• Lift pen straight up from skin. 
• Peresnik dvignite s kože navpično navzgor.
Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in rodents. 
Z adalimumabom niso bile narejene niti raziskave kancerogenosti, niti standardne ocene plodnosti ter poporodne toksičnosti, in sicer zato, ker ni ustreznih modelov za protitelo z omejeno navzkrižno reaktivnostjo z glodavskim TNF, in zaradi nastanka nevtralizirajočih
Adalimumab concentrations in the synovial fluid from several rheumatoid arthritis patients ranged from 31-96 % of those 
Koncentracije adalimumaba v sinovijski tekočini več bolnikov z revmatoidnim artritisom so bile od 31 do 96 % tistih v serumu.
Try not to cover the window with your • Press tip firmly against squeezed injection site. 
Okenca ne prekrijte z • Močno pritisnite na stisnjeno mesto injiciranja.
Patients treated with Cyltezo should be given the patient alert card. 
Bolniki, ki se zdravijo z zdravilom Cyltezo, morajo dobiti opozorilno kartico za
The primary endpoint in RA study V was the percent of patients who achieved an ACR 50 response at week 52. 
Primarni opazovani dogodek študije revmatoidnega artritisa V je bil odstotek bolnikov, ki so do 52. tedna dosegli odziv ACR 50.
Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks of rescue therapy with adalimumab, out of which 37 (56.9 %) had regained remission (ASDAS < 1.3) after 12 weeks of restarting the open-label treatment. 
Med 68 bolniki iz skupine namenjene prenehanju zdravljenja pri katerih je prišlo do ponovnega zagona bolezni, jih je 65 zaključilo 12 tednov trajajoče rešilno zdravljenje z adalimumabom, od tega jih je 37 (56,9 %) po 12 tednih ponovne odprte faze zdravljenja ponovno doseglo remisijo
Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body. 
Takoj obvestite zdravnika, če dobite simptome, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu
Health-related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a prespecified primary endpoint at week 52 in RA study III. 
Z zdravjem povezano kakovost življenja in telesno funkcijo so v štirih originalnih ustreznih in dobro kontroliranih študijah ocenjevali z indeksom invalidnosti z vprašalnikom HAQ (Health Assessment Questionnaire) in je bila v študiji revmatoidnega artritisa III vnaprej določen primarni opazovani dogodek po 52 tednih.
6 months 12 months 
8 do 12 let
Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. 
Sočasna uporaba adalimumaba z drugimi biološkimi DMARDS (tj. anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami, in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
• You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection. 
• O tehniki samoinjiciranja vas bo poučil zdravnik, medicinska sestra ali farmacevt.
Greater improvements at week 12 from baseline compared to placebo were demonstrated in skin-specific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (Study HS-I). 
Večje izboljšanje v 12. tednu so pokazali glede na izhodiščno vrednost v primerjavi s placebom glede z zdravjem povezane kakovosti življenja, specifične za kožo, merjene z dermatološkim indeksom kakovosti življenja (DLQI, Dermatology life quality index, v študijah HS-I in HS-II), glede bolnikovega splošnega zadovoljstva z zdravljenjem z zdravilom, merjenem z vprašalnikom o zadovoljstvu z zdravljenjem z zdravilom (TSQM, Treatment Satisfaction Questionnaire - medication, v študijah HS-I in HS-II), in glede telesnega zdravja, merjenega s seštevkom telesnih komponent v
Patients induced with 160/80 mg adalimumab achieved clinical remission versus placebo at week 8 in statistically significantly greater percentages in study UC-I (18 % vs. 9 % respectively, p = 0.031) and study UC-II (17 % vs. 9 % respectively, p = 0.019). 
Bolniki, ki so za indukcijo dobili 160/80 mg adalimumaba, so 8. teden v primerjavi s placebom dosegli klinično remisijo v statistično značilno večjem odstotku tako v študiji UC-I (18 % v primerjavi z 9 %, p = 0,031) kot v študiji UC-II (17 % v primerjavi z 9 %, p = 0,019).
This study evaluated the efficacy of adalimumab 40 mg every other week/methotrexate combination therapy, adalimumab 40 mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104 weeks. 
Ta študija je ocenila učinkovitost treh shem (kombinirano zdravljenje z adalimumabom 40 mg vsak drugi teden/metotreksatom, monoterapija z adalimumabom 40 mg vsak drugi teden in monoterapija z metotreksatom) za zmanjšanje znakov in simptomov ter hitrosti napredovanja sklepne okvare pri revmatoidnem artritisu v obdobju 104 tednov.
• If you are about to have a surgery or dental procedures, tell your doctor that you are taking Cyltezo. 
• Če boste imeli kirurški poseg ali poseg na zobeh, prosimo, obvestite zdravnika, da jemljete zdravilo Cyltezo.
You should record the date when the pen is first removed from refrigerator and the date after which it should 
Zapisati si morate datum, ko je bil injekcijski peresnik vzet iz hladilnika in datum, po katerem ga je
Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate versus placebo (see 
V obeh študijah je bil dokazan zgodnji in vzdrževan učinek adalimumaba na odstotek neuspeha zdravljenja proti placebu (glejte sliko 2).
• If you have mild heart failure and you are being treated with Cyltezo, your heart failure status must be closely monitored by your doctor. 
• Če imate blago srčno popuščanje in se zdravite z zdravilom Cyltezo, mora zdravnik natančno nadzorovati stanje vašega srčnega popuščanja.
In a study of 64 patients with rheumatoid arthritis that were treated with adalimumab, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils. 
V študiji 64 bolnikov z revmatoidnim artritisom, zdravljenih z adalimumabom, niso odkrili znakov zavrtja odložene preobčutljivosti, znižanja koncentracije imunoglobulinov ali spremembe števila efektorskih celic T in B, naravnih celic ubijalk, monocitov/makrofagov ali nevtrofilcev.
Your doctor may also prescribe an initial dose of 80 mg which may be administered one week prior to the 
Zdravnik lahko predpiše tudi začetni odmerek po 80 mg, ki se ga uporabi en teden pred začetkom
If retreatment with adalimumab is indicated, the above guidance on dose and treatment duration should be followed. 
Če je indicirano vnovično zdravljenje z adalimumabom, je treba upoštevati zgoraj navedena navodila
If new areas of damaged skin appear during or after therapy or if existing marks or areas of damage change appearance, tell your doctor. 
Če se vam med zdravljenjem ali po njem pojavijo novi predeli poškodb na koži, ali če se vam spremeni videz obstoječih znamenj ali predelov poškodb, morate o tem obvestiti
No other diseasemodifying anti-rheumatic drugs were allowed. 
Uporaba drugih imunomodulirajočih zdravil ni bila dovoljena.
Administration of live vaccines (e.g. BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months following the mother's last adalimumab injection during pregnancy. 
Uporaba živih cepiv (npr. BCG cepiva) pri dojenčkih, ki so bili izpostavljeni adalimumabu in utero, ni priporočljiva še 5 mesecev po materini zadnji injekciji adalimumaba med nosečnostjo.